Every earnings call for INDGN — management tone, guidance, KPIs and promise tracking, quarter by quarter.
INDGN · 6 transcripts · Healthcare · latest Q4 FY26Revenue (Q4 FY26) 10000 million (+33% YoY); Adjusted EBITDA (Q4 FY26) 1889 million (+23% YoY); PAT (Q4 FY26) 797 million. Q4 FY26 revenue exceeded ₹1,000 crores (₹10,000 million), a first for the company, growing 32.8% YoY.
Read full transcript & analysisRevenue 9421 million (+31% YoY); Adjusted EBITDA Margin 18.5%; PAT 1026 million (−6% YoY). Revenue reached INR 9,421 million, representing a robust 30.8% YoY and 17.1% QoQ growth.
Read full transcript & analysisRevenue 8042 million (+17% YoY); EBITDA Margin (Adjusted) 18.2%; PAT 1021 million (+11% YoY). Revenue reached ₹8,042 million, representing 17.1% YoY growth and 5.7% sequential growth.
Read full transcript & analysisIndegene FY25 Revenue 335 million USD; BioPharm Net Revenue (CY24) 29.2 million USD; BioPharm EBITDA (CY24) 7.9 million USD. Announced acquisition of BioPharm, a U.S.-based omnichannel marketing business, for a total purchase price of $104 million.
Read full transcript & analysisRevenue 28393 million (+10% YoY); EBITDA Margin 19.8%; PAT 4067 million (+21% YoY). FY25 Revenue reached ₹28,393 million, representing a 9.6% YoY growth.
Read full transcript & analysisRevenue ₹720 cr (+7% YoY); EBITDA Margin 20.8%; PAT ₹110 cr. Revenue reached ₹720.4 crores (INR 7,204 million), representing 7% YoY and 4.9% QoQ growth.
Read full transcript & analysis